Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

janssen-cilag ab - topiramatum inn - filmuhúðuð tafla - 50 mg

Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

janssen-cilag ab - topiramatum inn - hart hylki - 15 mg

Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - topiramatum inn - filmuhúðuð tafla - 100 mg

Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - topiramatum inn - filmuhúðuð tafla - 25 mg

Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - topiramatum inn - filmuhúðuð tafla - 50 mg

Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - topiramatum inn - filmuhúðuð tafla - 25 mg

Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - topiramatum inn - filmuhúðuð tafla - 50 mg

Euroopa Liit - islandi - EMA (European Medicines Agency)

bial - portela & ca, s.a. - eslikarbazepín asetat - flogaveiki - antiepileptics, - zebinix er ætlað sem viðbótarmeðferð hjá fullorðnum, unglingum og börnum eldri en 6 ára, með flogaveiki með eða án aukakvilla.

Euroopa Liit - islandi - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - voclosporin - lupus nephritis - Ónæmisbælandi lyf - lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class iii, iv or v (including mixed class iii/v and iv/v) lupus nephritis (ln).

Euroopa Liit - islandi - EMA (European Medicines Agency)

pfizer europe ma eeig  - axitinib - krabbamein, nýrnafrumur - prótín nt-hemlar - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.